Literature DB >> 1870376

The significance of facial patches and type I reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients.

M Hogeweg1, K U Kiran, S Suneetha.   

Abstract

Charts of 1226 paucibacillary leprosy patients, registered between 1982 and 1987 were reviewed for recent facial nerve damage, facial patches and the presence of Type I reaction. Twenty-six (2.1%) patients with recent lagophthalmos were identified. In a great majority (85%) patients with recent lagophthalmos showed significant patches over the malar region or around the eye, at the same side as the nerve damage together with clinical signs of Type I reaction. This combination of significant patches in certain locations and Type I reaction seems to be a pre-condition for facial nerve damage. The clinical implication is that a small group of patients may be identified, who are at risk of facial nerve damage. By examining these patients more carefully it will be possible to detect nerve damage early and to prevent permanent damage of the facial nerve by timely treatment with an appropriate steroid regimen.

Entities:  

Mesh:

Year:  1991        PMID: 1870376     DOI: 10.5935/0305-7518.19910016

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  7 in total

1.  Ocular leprosy.

Authors:  R de Soldenhoff
Journal:  Br J Ophthalmol       Date:  1992-07       Impact factor: 4.638

2.  Incidence of ocular morbidity among multibacillary leprosy patients during a 2 year course of multidrug therapy.

Authors:  E Daniel; T J Ffytche; P S S Sundar Rao; J H Kempen; M Diener-West; P Courtright
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

3.  Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy.

Authors:  E Daniel; T J Ffytche; J H Kempen; P S S Sundar Rao; M Diener-West; P Courtright
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

4.  Is leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda.

Authors:  K M Waddell; P R Saunderson
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

5.  Ocular complications in newly diagnosed borderline lepromatous and lepromatous leprosy patients: baseline profile of the Indian cohort.

Authors:  E Daniel; S Koshy; G Sundar Rao; P S S S Rao
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 6.  Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.

Authors:  José Augusto da Costa Nery; Fred Bernardes Filho; Juliana Quintanilha; Alice Miranda Machado; Soraya de Souza Chantre Oliveira; Anna Maria Sales
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

7.  Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B.

Authors:  Renuka Raju; Sujai Suneetha; Rupendra S Jadhav; MeherVani Chaduvula; Sara Atkinson; Suman Jain; Leo H Visser; Loretta Das; Ravindra Panhalkar; Vidyagouri Shinde; Parphananda P Reddy; Pramila Barkataki; Diana Nj Lockwood; Wim H Van Brakel; Lavanya M Suneetha
Journal:  Lipids Health Dis       Date:  2014-07-28       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.